Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis

Arthritis Research and Therapy

Volumn 15, Issue 5, 2013, Pages

  Crnkic Kapetanovic, Meliha ^a   Saxne, Tore ^a   Jönsson, Göran ^a   Truedsson, Lennart ^b   Geborek, Pierre ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANALGESIC AGENT; ANTIBIOTIC AGENT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PNEUMOCOCCUS VACCINE; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DAS28; DISEASE DURATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; GENDER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RHEUMATOID ARTHRITIS; SEROTYPE; SINGLE DRUG DOSE; SPONDYLOARTHROPATHY; TREATMENT RESPONSE; URINARY TRACT INFECTION; VACCINATION; ANTIBODY PRODUCTION; CLASSIFICATION; DRUG COMBINATION; IMMUNOLOGY; MIDDLE AGED; SEROTYPING; STATISTICAL MODEL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY FORMATION; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; LOGISTIC MODELS; MALE; METHOTREXATE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886569355     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4358     Document Type: Article

References (20)

1. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG. Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294:2043-2051. 10.1001/jama.294.16.2043, 16249418.
2. CDC. Advisory Committee on Immunization Practices Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2012, 61:40. [http://www.cdc.gov/vaccines/schedules/hcp/adult.html], CDC. Advisory Committee on Immunization Practices.
3. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Müller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011, 70:414-422. 10.1136/ard.2010.137216, 21131643.
4. Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 2011, 63:3723-3732. 10.1002/art.30580, 21834061.
5. EudraCT [https://eudract.ema.europa.eu], EudraCT.
6. Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, Benjamin W, Quataert SA, Hildreth S, Sikkema DJ, Käyhty H, Jonsdottir I, Nahm MH. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003, 10:514-519. 164258, 12853378.
7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
8. St Clair EW. Good and bad memories following rituximab therapy. Arthritis Rheum 2010, 62:1-5.
9. van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, Voskuyl A, de Haan A, Westra J, Kallenberg CG, Bijl M. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010, 62:75-81. 10.1002/art.25033, 20039396.
10. Bingham CO, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010, 62:64-74. 10.1002/art.25034, 20039397.
11. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open label extension analysis. Arthritis Rheum 2007, 56:3896-3908. 10.1002/art.23059, 18050221.
12. Tay L, Leon F, Vratsanos G, Raymond R, Corbo M. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther 2007, 9:R38. 10.1186/ar2174, 1906816, 17425783.
13. Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA, Bonfa E. Abatacept severely reduces the immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013, 65:476-480. 10.1002/acr.21838, 22949223.
14. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:106-111. 10.1093/rheumatology/kei193, 16287919.
15. Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, Maini RN, Feldmann M. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994, 94:749-760. 10.1172/JCI117394, 296155, 8040330.
16. Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, Kishimoto T. The essential role of B cell stimulatory factor (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988, 167:332-344. 10.1084/jem.167.2.332, 2188837, 3258006.
17. Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 2012, 71:2006-2010. 10.1136/annrheumdis-2012-201950, 3595981, 22887851.
18. Costelloe KE, Smith SH, Callard RE. Interleukin 6 is not required for antigen-specific antibody responses by human B cells. Eur J Immunol 1993, 23:984-987. 10.1002/eji.1830230436, 8458386.
19. Plotkin S. Correlates of protection induced by vaccination. Minireview. Clin Vaccine Immunol 2010, 17:1055-1065. 10.1128/CVI.00131-10, 2897268, 20463105.
20. Henriques Normark B, Kalin M, Ortqvist A, Akerlund T, Olsson Liljeqvist B, Hedlund J. Dynamics of penicillin-susceptible clones in invasive pneumococcal disease. J Infect Dis 2001, 184:861-869. 10.1086/323339, 11550126.